IE871210L - Tissue plasminogen activator - Google Patents
Tissue plasminogen activatorInfo
- Publication number
- IE871210L IE871210L IE871210A IE121087A IE871210L IE 871210 L IE871210 L IE 871210L IE 871210 A IE871210 A IE 871210A IE 121087 A IE121087 A IE 121087A IE 871210 L IE871210 L IE 871210L
- Authority
- IE
- Ireland
- Prior art keywords
- tissue
- plasminogen activator
- tissue plasminogen
- medicament
- damage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Tissue plasminogen activator (t-PA), optionally together with superoxide dismutase (SOD), is used to manufacture a medicament for use in the inhibition of damage to jeopardised tissue during blood reperfusion. The medicament is for preventing damage to tissue following ischaemic attack, e.g. in myocardial tissue, when blood supply is restored.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86204686A | 1986-05-12 | 1986-05-12 | |
US06/862,057 US4976959A (en) | 1986-05-12 | 1986-05-12 | T-PA and SOD in limiting tissue damage |
Publications (2)
Publication Number | Publication Date |
---|---|
IE871210L true IE871210L (en) | 1987-11-12 |
IE59895B1 IE59895B1 (en) | 1994-04-20 |
Family
ID=27127662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE121087A IE59895B1 (en) | 1986-05-12 | 1987-05-11 | Medicaments containing tissue plasminogen activator |
Country Status (13)
Country | Link |
---|---|
JP (1) | JPH0680015B2 (en) |
AU (1) | AU600724B2 (en) |
BE (1) | BE1001425A4 (en) |
CH (1) | CH672989A5 (en) |
DE (1) | DE3715662A1 (en) |
DK (1) | DK237187A (en) |
FR (1) | FR2600895B1 (en) |
GB (1) | GB2194886B (en) |
IE (1) | IE59895B1 (en) |
LU (1) | LU86875A1 (en) |
NL (1) | NL8701113A (en) |
NZ (1) | NZ220260A (en) |
SE (1) | SE8701921L (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0780784B2 (en) * | 1987-10-23 | 1995-08-30 | 宇部興産株式会社 | Myocardial ischemic injury therapeutic agent based on microcirculatory disorder |
NZ230808A (en) * | 1988-10-24 | 1993-04-28 | Squibb & Sons Inc | Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent |
DE4038563A1 (en) * | 1990-12-04 | 1992-06-11 | Gruenenthal Gmbh | USE OF SUPEROXIDE DISMUTASES FOR PROPHYLAXIS AND / OR TREATMENT OF ORGAN FAILURE IN RISK PATIENTS WITH POLYTRAUMA |
DE19518625C2 (en) * | 1995-05-24 | 1997-08-07 | Buescher Pebueso Beton | Process for sealing concrete pipes and a concrete pipe suitable for carrying out the process |
US8680059B2 (en) | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
EP1138692A1 (en) | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
US20030220258A1 (en) | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
US6844315B2 (en) | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
US7175679B2 (en) | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
US6921751B1 (en) | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
EP1300418A1 (en) | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
US7358330B2 (en) | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
US7576174B2 (en) | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
US7501391B2 (en) | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
US7517529B2 (en) | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
SG163567A1 (en) | 2005-07-05 | 2010-08-30 | Biotempt Bv | Treatment of tumors |
EP1864692A1 (en) | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
US8652476B2 (en) | 2009-07-27 | 2014-02-18 | Niigata University | Pharmaceutical composition for treating ischemic events |
WO2011013668A1 (en) * | 2009-07-27 | 2011-02-03 | 国立大学法人新潟大学 | Pharmaceutical composition for treatment of ischemic events |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8003402A (en) * | 1980-06-11 | 1982-01-04 | Leuven Res & Dev Vzw | NEW PLASMINOGEN ACTIVATOR AND PHARMACEUTICAL PREPARATION WITH THROMBOLYTIC ACTION. |
DE3382389D1 (en) * | 1982-12-14 | 1991-10-02 | South African Inventions | PLASMINOGEN ACTIVATOR. |
JPS59196824A (en) * | 1983-04-21 | 1984-11-08 | Kowa Co | Adsorption inhibitor |
US4929444A (en) * | 1985-05-28 | 1990-05-29 | Burroughs Wellcome Co. | Low pH pharmaceutical formulation containing t-PA |
NZ216306A (en) * | 1985-05-28 | 1989-10-27 | Wellcome Found | Pharmaceutical compositions containing tissue plasminogen activator |
WO1987006831A1 (en) * | 1986-05-15 | 1987-11-19 | Emory University | Composition and method for treating a thrombus and embolus |
-
1987
- 1987-05-11 DK DK237187A patent/DK237187A/en not_active Application Discontinuation
- 1987-05-11 LU LU86875A patent/LU86875A1/en unknown
- 1987-05-11 GB GB8711058A patent/GB2194886B/en not_active Expired - Fee Related
- 1987-05-11 IE IE121087A patent/IE59895B1/en not_active IP Right Cessation
- 1987-05-11 SE SE8701921A patent/SE8701921L/en unknown
- 1987-05-11 DE DE19873715662 patent/DE3715662A1/en active Granted
- 1987-05-11 BE BE8700510A patent/BE1001425A4/en not_active IP Right Cessation
- 1987-05-11 CH CH1788/87A patent/CH672989A5/de not_active IP Right Cessation
- 1987-05-11 JP JP62114386A patent/JPH0680015B2/en not_active Expired - Lifetime
- 1987-05-11 NL NL8701113A patent/NL8701113A/en not_active Application Discontinuation
- 1987-05-11 NZ NZ220260A patent/NZ220260A/en unknown
- 1987-05-11 AU AU72704/87A patent/AU600724B2/en not_active Ceased
- 1987-05-11 FR FR8706551A patent/FR2600895B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
GB8711058D0 (en) | 1987-06-17 |
BE1001425A4 (en) | 1989-10-31 |
GB2194886B (en) | 1990-04-25 |
DK237187A (en) | 1987-11-13 |
LU86875A1 (en) | 1988-01-20 |
FR2600895B1 (en) | 1993-12-24 |
AU7270487A (en) | 1987-11-19 |
CH672989A5 (en) | 1990-01-31 |
FR2600895A1 (en) | 1988-01-08 |
SE8701921L (en) | 1987-11-13 |
NZ220260A (en) | 1990-07-26 |
JPS6322026A (en) | 1988-01-29 |
GB2194886A (en) | 1988-03-23 |
AU600724B2 (en) | 1990-08-23 |
NL8701113A (en) | 1987-12-01 |
SE8701921D0 (en) | 1987-05-11 |
JPH0680015B2 (en) | 1994-10-12 |
IE59895B1 (en) | 1994-04-20 |
DK237187D0 (en) | 1987-05-11 |
DE3715662A1 (en) | 1987-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IE871210L (en) | Tissue plasminogen activator | |
AU6414498A (en) | Composition comprising immunoglobulin | |
AU4135289A (en) | Pharmaceutically active combination | |
GB2207351B (en) | Neutral endopeptidase inhibitors as agents for diuresis, natriuresis and thus lowering of blood pressure | |
CA2088343A1 (en) | Stable fibrinogen solution | |
DE69414114T2 (en) | COLD STERILIZER WITH EXTENDED ACTIVITY | |
EP0278696A3 (en) | An arg-serpin human plasminogen activator inhibitor designated pai-2 | |
EP1310256A3 (en) | Use of prostaglandin A or its derivatives for the treatment of psoriasis | |
TW337997B (en) | Pharmaceutical preparation containing plasminogen activators | |
ES2013500A6 (en) | Variants of plasminogen activators and processes for their production. | |
SG48282A1 (en) | Preparation of factor ix | |
JPS5587712A (en) | Skin cosmetic | |
EP0796262A4 (en) | 7-alkylidene cephalosporanic acid derivatives and methods of using the same | |
SE9602644D0 (en) | New use | |
EP0208785A4 (en) | Fibrinophilic urokinase complex and process for its preparation. | |
JPS5692217A (en) | Easily absorbable enzyme preparation | |
ES2000033A6 (en) | Liquid stable anthelmintic and fungicidal composition based on bithionol sulfoxide. | |
IE791183L (en) | Phenylpropynylamino benzoic acids | |
EP0340933A3 (en) | Heparin-containing formulations | |
CA2075901A1 (en) | Tissue plasminogen activator having fibrin specific properties | |
AU2001288229A1 (en) | An advantageous carrier solution for vitrifiable concentrations of cryoprotectants, and compatible cryoprotectant mixtures | |
AU6997287A (en) | The application of tissue plasminogen activator and oxypurinol in dissolving blood clots and in preventing damage to ischaemic tissue during reperfusion | |
WO2000021508A3 (en) | Novel therapeutic use of compounds with beta-3-agonist activity | |
WO2002008174A8 (en) | Phenylethylamine derivatives and their use in the treatment of melanoma | |
EP0277751A3 (en) | Modified fibrinolytic enzyme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed |